Topic List : Cancer
Young scientists win Parker Institute awards
The awards are designed to help train the next generation of scientists in cancer immunotherapy by supporting promising young researchers doing innovative work that has the potential for great impact.
Data sifting finds hidden gene partnerships
Targeting backup biological pathways often used by cancers can lead to more efficient drug development and less-toxic therapies. Stanford researchers have developed a new way to identify these pathways.
Cancer therapy may work in unexpected way
An antibody to the cell receptor PD-1 may launch a two-pronged assault on cancer by initiating attacks by both T cells and macrophages, a Stanford study has found.
First possible drug treatment for lymphedema
Collaboration between two Stanford labs has resulted in the discovery of a molecular cause for lymphedema and the first possible drug treatment for it.
Fibrotic diseases united by common pathway
A common signaling pathway unites diverse fibrotic diseases in humans, Stanford researchers have found. An antibody called anti-CD47, which is being tested as an anti-cancer agent, reverses fibrosis in mice.
Too many unnecessary double mastectomies?
Women with breast cancer do not receive timely genetic testing or have adequate access to effective genetic counseling, which may compromise treatment decisions, according to research from Stanford and the University of Michigan.
Ronald Levy and Howard Chang honored
Stanford cancer researchers Ronald Levy and Howard Chang have been named Outstanding Investigators by the National Cancer Institute. They were awarded grants of up to $7 million over six years to advance their studies.
Diagnosing cancer without biopsy
A Stanford-led team of researchers has developed tiny bubbles that bind to malignant tumors, making them visible to ultrasound imaging.
Grants awarded for cancer immunotherapy
The Parker Institute for Cancer Immunotherapy at Stanford hands out its first grants to researchers who hope to translate scientific discoveries into new therapies for cancer patients.
Antibody effective against brain tumors
Antibodies against the CD47 “don’t eat me” signal were shown in mice to be a safe and effective way to target five kinds of pediatric brain tumors, according to Stanford researchers.